India Supreme Court: Blasts Private Hospital Drug Markup, Cites 10x Inflation

• The Supreme Court of India criticized private hospitals for operating as profit-driven industries, not service providers, in the case of `Kishan Chand Jain v. Union of India`.
• Justices Vikram Nath and Sandeep Mehta highlighted that corporate hospitals compel patients to buy overpriced medicines from in-house pharmacies and refuse treatment for outside drugs.
• The Court previously noted a cancer drug with a Price to Retailer (PTR) of ₹2,700 was sold at a Maximum Retail Price (MRP) of ₹27,000, calling it "broad daylight dacoity."
• Corporate hospitals also receive full government reimbursement based on these inflated MRPs for patients under welfare schemes.

By categorizing corporate hospitals as industries rather than service providers, the Court challenges the fundamental ethos of medical care, emphasizing that patient well-being should supersede profit motives.

The Supreme Court of India recently delivered a sharp critique of the commercialization prevalent within the nation's private healthcare sector. Justices Vikram Nath and Sandeep Mehta, presiding over the case of `Kishan Chand Jain v. Union of India`, observed that corporate hospitals frequently operate more like profit-driven enterprises than essential service providers. This approach, the Court noted, places an undue burden on ordinary citizens and taxpayers who are forced to contend with exorbitant markups on essential medicines.

A key point of contention highlighted by the Bench was the practice of private hospitals compelling admitted patients to procure all necessary medications exclusively from their in-house pharmacies. These drugs are often sold at significantly inflated retail prices. Furthermore, the Court noted that patients attempting to bring medicines from external sources are often denied treatment, leaving them in a precarious position and undermining their autonomy in healthcare choices.

During the proceedings, the Supreme Court revisited earlier observations regarding a staggering ten-fold price disparity identified in a specific cancer drug. The Price to Retailer (PTR) for this medication was ₹2,700, yet its Maximum Retail Price (MRP) reached an astonishing ₹27,000. This dramatic difference was previously characterized by the Court as an "absolute rampage and carnage" and "broad daylight dacoity," underscoring the severity of the issue.

The Bench further elaborated on how this inflated pricing structure extends its impact beyond individual patients to the public exchequer. When patients receive treatment under various government-sponsored welfare schemes, corporate hospitals secure full reimbursement from state funds based on these artificially high MRPs. For instance, the Court cited an example where a drug with a PTR of approximately ₹3,000 was sold at an MRP of ₹27,000 within corporate hospital settings, illustrating the significant financial discrepancy.

These observations by the Court on `corporate hospital medicine pricing India` highlight a systemic issue where the pursuit of financial gain appears to overshadow patient rights and access to affordable treatment.

This judicial scrutiny of `India Supreme Court private hospital drug markup` practices suggests a potential shift towards greater regulatory oversight in the sector. The Court's observations underline the urgent need for mechanisms to control drug pricing and ensure transparency, especially given the vulnerability of patients and the financial strain on public welfare programs. The `healthcare commercialization ruling India` could prompt legislative action aimed at curbing exploitative practices and safeguarding the interests of patients across the country.

Healthcare providers and their legal counsel in India should anticipate increased regulatory scrutiny and potential legislative action concerning drug pricing and mandatory in-house pharmacy purchases, given the Supreme Court's strong criticism of commercialization in private healthcare. Compliance officers should review internal policies on drug procurement, pricing, and patient choice to mitigate legal and reputational risks.

Source: Original reporting via Bar and Bench